GÖTTINGEN — Sartorius, a renowned life science group, is embarking on an expanded collaboration with NVIDIA, a leader in AI-powered computing platforms, to drive the development of new and improved therapies. This collaboration aims to merge Sartorius’ profound expertise in life sciences and bioprocessing with NVIDIA’s cutting-edge AI technologies to expedite biopharma drug discovery and manufacturing processes. Prof. Dr. Oscar-Werner Reif, Sartorius’ Chief Technology Officer, expressed optimism about the potential of integrating AI solutions with life science expertise to simplify and accelerate advancements in biopharmaceuticals, ultimately benefiting patients, according to a press release published on EuropaWire.

Since 2020, Sartorius has been leveraging NVIDIA’s technology to enhance its instruments, facilitating edge computing applications in its live-cell imaging platform for AI assays in the lab. This partnership has focused on developing predictive AI models for stem cell-derived organoids, aiming to replace animal models in drug discovery and precision medicine. Additionally, Sartorius utilizes NVIDIA solutions for predictive bioprocess design and simulation tools to manufacture innovative therapies.

The expanded collaboration will see Sartorius integrating NVIDIA’s Clara suite of AI-powered computing platforms, software, and services into its ecosystem. This integration aims to create and commercialize robust foundational models based on Sartorius’ extensive data sets, providing customers with new predictive AI models, tools, and simulations across various applications. Looking ahead, the partnership will explore advanced technologies such as computer-based design and simulation of complex 3D-bioprinted spheroids and organoids, as well as synthetic biological pathways and organisms designed based on Sartorius cell lines to produce novel therapeutic agents and therapies.